Gsk (GLAXF) Notes Payables (2016 - 2025)
Historic Notes Payables for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$3.9 billion.
- Gsk's Notes Payables fell 170814.07% to -$3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 billion, marking a year-over-year decrease of 170814.07%. This contributed to the annual value of -$3.0 billion for FY2024, which is 18581.81% down from last year.
- Latest data reveals that Gsk reported Notes Payables of -$3.9 billion as of Q3 2025, which was down 170814.07% from -$366.9 million recorded in Q2 2025.
- Gsk's Notes Payables' 5-year high stood at $4.9 billion during Q4 2021, with a 5-year trough of -$7.0 billion in Q2 2021.
- Its 5-year average for Notes Payables is -$600.0 million, with a median of -$299.4 million in 2022.
- As far as peak fluctuations go, Gsk's Notes Payables soared by 9436.96% in 2021, and later tumbled by 322863.29% in 2024.
- Gsk's Notes Payables (Quarter) stood at $4.9 billion in 2021, then decreased by 4.51% to $4.6 billion in 2022, then dropped by 24.68% to $3.5 billion in 2023, then crashed by 186.35% to -$3.0 billion in 2024, then fell by 27.79% to -$3.9 billion in 2025.
- Its last three reported values are -$3.9 billion in Q3 2025, -$366.9 million for Q2 2025, and -$2.5 billion during Q1 2025.